Thursday, October 01, 2020 6:49:56 PM
By Nick Waddell
7:00 AM
October 1, 2020
The market has been rough on Canadian cannabis name Organigram (Organigram Stock Quote, Chart, News TSX:OGI) but there’s a bit of good news related to its biosynthesis equity partner, which should be seen as a sign of OGI’s potential going forward, says Raymond James analyst Rahul Sarugaser.
In an update to clients Wednesday, Sarugaser reiterated his “Market Perform 3” rating on OGI, whose share price has dropped 56 per cent in value year-to-date.
On Monday, Montreal-based Hyasynth Biologicals announced it has made its first sale of cannabidiol (CBD) produced via biosynthesis from yeast. Not disclosing at this time information on the buyer, Hyasynth, who is Organigram’s CBD biosynthesis equity partner, has said that its proprietary process is profitable right away and that the company is now positioned to move toward large scale commercial manufacturing which it aims to achieve during 2021.
“Our head start in this area was a key factor in us being the first to reach commercial sale of CBD and CBDa produced from a reliable and sustainable source,” said Kevin Chen, CEO of Hyasynth, in a press release. “We’ve assembled an excellent team of researchers, built an IP portfolio across many cannabinoids, and our production & sale achievement is one of the last checkpoints before we make our solution available worldwide.”
In his report, Sarugaser pointed out that Organigram was one of the first cannabis companies to move on cannabinoid biosynthesis through a $10-million investment in Hyasynth back in 2018, which, to the analyst, “confirmed to us OGI’s future-facing, technology-prioritizing attitude to business.”
“OGI's conviction in cannabinoid biosynthesis was an early hedge on the botanical cannabis space, providing the company optionality on its future cannabinoid supply chains. Derivative cannabis products—Cannabis 2.0, e.g., edibles, vapes, topicals beverages, concentrates— comprise an escalating share of the global cannabis market, and the pure cannabinoids produced by fermentation are extremely fungible with plant-derived cannabinoids,” Sarugaser wrote.
“So, while Hyasynth is still in the early stages of scaling its process to reach commercial production volumes, we see this announcement as a positive for OGI,” he said.
Sarugaser said Organigram’s focus on Cannabis 2.0 products, especially vapes and chocolates, would allow it to “immediately incorporate” Hyasynth’s cannabinoids into its current product offerings, leading to reduced input costs and stabilized batch-to-batch variability. In essence, Sarugaser feels like OGI’s investment in Hyasynth is beginning to pay off.
“OGI has, indeed, been having a hard time on the markets recently, hitting new 52-week lows this week, but this news of positive progress from its biosynthesis partner, Hyasynth, illustrates to us that OGI has the capacity to develop a suite of innovative, technology-empowered products as the cannabis sector migrates from its reliance on noisy, inconsistent, expensive cannabis plant-derived cannabinoids toward pure, consistent, cost-effective APIs produced by alternate manufacturing modalities such as
biosynthesis,” Sarugaser wrote.
Looking ahead for OGI, Sarugaser thinks the company will generate fiscal 2020 (year end August) revenue and EBITDA of $91 million and negative $20 million, respectively, and fiscal 2021 revenue and EBITDA of $114 million and $23 million, respectively.
Recent OGI News
- US Futures Remain Steady Amid Wall Street Caution Ahead of April PPI Report • IH Market News • 05/14/2024 11:18:01 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/14/2024 11:17:16 AM
- Organigram Reports Second Quarter Fiscal 2024 Results • Business Wire • 05/14/2024 10:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/08/2024 03:29:51 PM
- Organigram to Report Second Quarter Fiscal 2024 Results on May 14, 2024 • Business Wire • 05/08/2024 12:00:00 PM
- Organigram Recognized for Executive Gender Diversity by the Globe & Mail’s Women Lead Here Report for the Fourth Consecutive Year • Business Wire • 04/08/2024 10:00:00 AM
- Organigram’s Popular SHRED Brand Surpasses $200 Million in Yearly Retail Sales • Business Wire • 04/03/2024 12:06:00 PM
- Organigram Successfully Closes Previously Announced Underwritten Public Offering • Business Wire • 04/02/2024 12:51:00 PM
- Organigram Announces Pricing of Overnight Marketed Public Offering • Business Wire • 03/27/2024 12:56:00 PM
- Organigram Announces Launch of Overnight Marketed Public Offering • Business Wire • 03/26/2024 11:06:00 PM
- Organigram Invests in U.S. Based Open Book Extracts Representing Inaugural Jupiter Investment • Business Wire • 03/26/2024 05:36:00 PM
- Organigram Receives Health Canada’s Final Redetermination on Jolts • Business Wire • 03/22/2024 11:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/28/2024 03:42:13 PM
- Organigram Applauds the Standing Committee on Finance’s Recommendation on Excise Duty • Business Wire • 02/28/2024 01:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/13/2024 12:23:18 PM
- Organigram Reports First Quarter Fiscal 2024 Results • Business Wire • 02/13/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/07/2024 02:25:53 PM
- Organigram to Report First Quarter Fiscal 2024 Results on February 13, 2024 • Business Wire • 02/07/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/31/2024 01:36:42 PM
- Organigram Completes First Shipment to Germany, Extending its International Reach • Business Wire • 01/31/2024 11:00:00 AM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 01/25/2024 10:23:26 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/24/2024 10:30:11 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/24/2024 02:23:37 PM
- Organigram Announces the First Tranche Closing from BAT Investment • Business Wire • 01/24/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/19/2024 12:38:06 PM
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM